AstraZeneca, the UK’s largest drugmaker, has allegedly contacted American biopharmaceutical company Gilead Sciences regarding a potential merger deal in an informal approach and aimed at testing its US rivals interest in the deal.
Previously, Gilead has focused on obtaining smaller pharmaceutical companies, formerly shifting away from more extensive merger deals with Big Pharma companies. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
